From our $10M PTE Initiative to our more recent astrocyte biomarker work, CURE Epilepsy has partnered closely with the government to accelerate progress on traumatic brain injuries for veterans and civilians alike by improving understanding of biological underpinnings.
“The PTE Initiative provided funding for a high-risk, high-impact study of a potential mechanism for PTE. Our findings have provided key preliminary data that have substantially “de-risked” the project. So now it is low-risk, high-impact!”
Kevin Staley, MD
Mass General
CURE Epilepsy’s new PABI project builds off the astrocyte findings in the original PTE Initiative. Funded by the US Department of Defense’s Congressionally-Directed Medical Research Program (CDMRP) Epilepsy Research Program, this new initiative aims to track how astrocytes change in the brain after TBI and before PTE onset. A collaborative effort across multiple scientific teams, PABI will look for signs from astrocytes that predict PTE in mouse models. One team will also study archived blood samples collected from people at various time points after a TBI, to track changes in measures of inflammation. This may reveal a distinctive “signature” that discriminates those who develop PTE from those who do not.